• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report: Novartis eyes sale for Alcon lens business

January 26, 2017 By Sarah Faulkner

Report: Novartis eyes sale for Alcon lens businessNovartis (NYSE:NVS) said yesterday that it is considering selling its Alcon eye care business and will buy back up to $5 billion worth of shares over the next 12 months, in an effort to reorganize after a tough year.

The company’s profits dropped -11% to $936 million in the 3 months ended Dec. 31, while sales fell -2% to $12.32 billion.

Novartis bought Alcon from Nestle for $52 billion in 2010 under the leadership of former CEO & chairman Daniel Vasella. Alcon’s sales have struggled in recent years and the company has undergone changes to its leadership team. New division head Mike Ball has been charged with halting the company’s revenue slide in case the unit is sold.

Novartis reportedly said it could sell Alcon, spin it off in an IPO or keep it. “We’ve not ruled anything out, all options are on the table,” CEO Joe Jimenez said, Reuters reported. Jimenez told investors to keep an eye out for an update by the end of 2017.

Following the news of the $5 billion buy-back offer, Moody’s downgraded Novartis’ debt rating outlook from stable to negative. Moody’s reportedly said that the company’s borrowing capacity would be weakened by offering a debt-financed share buyback program at a time when its sales are stagnant.

Jimenez also said that Novartis expects to see growth in 2018, as its top-selling blood cancer drug’s patent expires and as newer drugs take off in the market.

“Unfortunately, 2017 is going to look a lot like 2016,” Jimenez said, according to the news outlet. “We expect the next growth phase of this company to begin toward the end of this year.”

In November, Novartis backed off a 2016 start date to test its autofocusing contact lens in clinical trials, but it told Reuters that the product is “progressing steadily” in its collaboration with Google (NSDQ:GOOGL).

In 2014, Jimenez said he hoped the lens would be on the market in 5 years and last year he said his company’s Alcon eye care unit was on track to begin clinical testing in 2016.

Novartis and Google inked a partnership 2 years ago to develop an autofocusing lens for people with presbyopia and a lens that can measure blood glucose levels in diabetes patients.

The noninvasive lenses for diabetic patients could present an alternative to finger-pricks and an autofocusing lens could help patients whose ability to focus degenerates as they age. The company has not commented on when testing for the diabetes lens will start, according to Reuters.

Filed Under: Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Alcon, Novartis

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS